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P U B L I S H E D B Y E L S E V I E R I N C .LettersPrioritizing Proteomics
Assay Development for
Clinical TranslationThe human genome consists ofmore than 20,000 genes;
about one-half have been found in microarray experi-
ments to be expressed in the heart. We asked which
of the w10,000 cardiac proteins are most studied in
and are thus essential to cardiac research, for which,
perhaps surprisingly, no objective measures yet existed.
This question is relevant to clinical investigations, basic
research, and biomarker discovery, because high-quality
quantiﬁcation assays are available for relatively few
proteins. Selected reaction monitoring (SRM) is a tar-
geted mass spectrometry technique that allows the
quantiﬁcation of virtually any user-speciﬁed proteins
with high sensitivity (w20 amol) and speciﬁcity (1). SRM
assays have important advantages over conventional
immunoblots or enzyme-linked immunosorbent assays
in their precision, throughput, and ability to target post-
translational modiﬁcations, but adoption rates in basic/
clinical research remain poor. It is thought that chal-
lenges formethod developers to strategize development
to prioritize important and popular proteins contribute
to a bottleneck in technology dissemination (2).
To assess protein importance objectively, we per-
formed a large-scale bibliometric analysis of the
24 million research papers curated on PubMed. We
used the search terms “heart [MeSH term/All ﬁelds]
or cardiac [All ﬁelds]” to retrieve cardiac-related
articles, then tallied the occurrences of each protein
being referenced to the retrieved papers on NCBI
Gene using a new software tool (BD2KPubMed). In
total, we retrieved w1.4 million cardiac-related pa-
pers referenced to 8,325 distinct human proteins.
Table 1 lists the top 15 cardiac proteins with the most
publications.
The data underline an intense focus of the majority
of cardiac research on relatively few proteins. The
50 most-studied proteins accounted for 19% of all
referenced cardiac publications, averaging 150
studies each. Publications declined precipitously
after the 50th protein, with the next 50 proteins
having one-third as many publications, whereas 84%
of the investigated proteins had #5 publications. Themost-studied human protein is natriuretic peptide B
(BNP/NPPB), a routinely utilized clinical marker for
evaluation and risk stratiﬁcation of heart failure pa-
tients, which alone accounts for 1.3% of all publica-
tions referenced to cardiac proteins. Following BNP
are angiotensin-converting enzyme and NaV1.5 (so-
dium channel protein type 5), accounting for 1.0%
and 0.9% of referenced publications, respectively.
Intriguingly, there exists a marked discrepancy
between the most studied proteins in humans and in
mice. Among the top 50 mouse and human proteins,
only 17 are shared. BNP ranks 61st in mouse studies,
which instead featured homeobox protein NKX2-5/
tinman as the top protein. NKX2-5 is a master regu-
lator of cardiac differentiation/development that ac-
counts for 1% of publications in mice but ranks 29th
in humans. We suggest that this discrepancy reﬂects
different priorities between basic and clinical in-
vestigations. Many human proteins have clinical
values prior to further reports on mechanisms of ac-
tion. The top 20 human proteins alone contained 9
secreted proteins that are known disease biomarkers,
versus 4 in mice. The popularity of BNP increased
following its adoption as a clinical biomarker of heart
failure circa 2003. In contrast, top mouse proteins
include signal transducers in developmental path-
ways that have not been sufﬁciently translated to
humans. Gene ontology analysis corroborates func-
tional differences: the top 50 human proteins
are signiﬁcantly enriched in regulation of transport
(p < 4.7  1021) and contractility (p < 8.3  1018),
whereas the top 50 mouse proteins are enriched in
heart morphogenesis (p < 2.1  1035) and cardiac
muscle development (p < 4.2  1029).
The measurement of protein abundance is essential
to biomedical research, where the availability of high-
quality protein quantiﬁcation tools can dictate the
pace of discovery (3). There are currently few experi-
mentally veriﬁed SRM assays, and most available as-
says await further validation in relevant cohorts.
We present here a resource to comprehend research
trends, and a list of high-priority proteins that merit
expedited assay development and clinical translation.
These most-studied proteins provide opportuni-
ties for developers to target community interests in
cardiovascular research, but complementary metrics
may also be employed (e.g., hub proteins in biological
TABLE 1 Top 15 Most-Studied Cardiac Proteins in Human/Mouse
Rank
No. of
Publications UniProt Gene Name Protein Name Cardiovascular Relevance
MS
Method
Expt.
Assay
Human
1 532 P16860 NPPB Natriuretic peptides B Secreted heart failure marker C C
2 379 P12821 ACE Angiotensin-converting enzyme Vasoconstrictor activity C C
3 343 Q14524 SCN5A Sodium channel protein type 5
subunit alpha
EC coupling C C
4 325 Q12809 KCNH2 Potassium voltage-gated
channel H2
Repolarization, ventricular action
potential
C
5 287 P02741 CRP C-reactive protein Inﬂammation marker C C
6 283 P02649 APOE Apolipoprotein E Cholesterol and triglyceride
regulation
C C
7 254 P51787 KCNQ1 Potassium voltage-gated
channel KQT1
Modulate action potential
duration
C
8 237 P29474 NOS3 Nitric oxide synthase, endothelial Vasoprotection against
atherosclerosis
C C
9 218 P45379 TNNT2 Troponin T, cardiac muscle Infarct marker in plasma;
contractility
C C
10 211 P19429 TNNI3 Troponin I, cardiac muscle Infarct marker in plasma;
contractility
C C
11 209 P01375 TNF Tumor necrosis factor Inﬂammatory marker C C
12 202 P05231 IL6 Interleukin-6 Inﬂammatory marker C C
13 174 P42898 MTHFR Methylenetetrahydrofolate
eductase
Association with congenital heart
defects
C
14 168 P07550 ADRB2 Beta-2 adrenergic receptor Catecholamine signaling C
15 166 P08588 ADRB1 Beta-1 adrenergic receptor Catecholamine signaling C
Mouse
1 377 P42582 Nkx2-5 Homeobox protein Nkx-2.5 Tissue development and
differentiation
C
2 337 Q08481 Pecam1 Platelet endothelial cell
adhesion mol
Angiogenesis C
3 253 Q08369 Gata4 Transcription factor GATA-4 Gene expression control C
4 253 P62737 Acta2 Actin, aortic smooth muscle Cell structure C
5 252 P05125 Nppa Natriuretic peptides A Cardiovascular homeostasis C
6 249 P08226 Apoe Apolipoprotein E Cholesterol and triglyceride
regulation
C
7 244 P70313 Nos3 Nitric oxide synthase,
endothelial
Vasoprotection against
atherosclerosis
C
8 224 P51667 Myl2 Myosin light chain 2,
ventricular/cardiac
Regulation of myosin
ATPase activity
C
9 206 P23242 Gja1 Gap junction alpha-1
protein
Major protein of gap
junctions in the heart
C
10 176 P11531 Dmd Dystrophin Stabilization of actin
ﬁlaments
C
11 144 P61372 Isl1 Insulin gene enhancer
protein ISL-1
Regulation of insulin
signaling
C
12 142 Q01231 Gja5 Gap junction alpha-5
protein
Gap junction component C
13 140 Q02566 Myh6 Myosin-6 Muscle contractility C
14 139 P04202 Tgfb1 Transforming growth
factor beta-1
Cellular proliferation and
differentiation
C
15 139 P70326 Tbx5 T-box transcription
factor TBX5
Cardiomyocyte
differentiation
C
Availability of SRM methods and assays are from SRMAtlas (5).
EC ¼ excitation-contraction; Expt. ¼ experimental; MS ¼ mass spectrometry; UniProt ¼ Universal Protein Resource.
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203networks). Developmental priority may further be
inﬂuenced by the scale required in clinical applications
(50 to 5,000þ samples), which often lies beyond the
domain of basic research (10 to 100 samples). To
accelerate translation, we suggest that more concertedbasic clinical collaborations to optimize sample and
data sharing pipelines are in order.
Users interested in identifying high-impact pro-
teins in other topics can download BD2KPubMed and
additional methodology information (4).
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Clinical Forms of
Neurally-Mediated Syncope
Central or peripheral baroreceptor reﬂex abnor-
malities, alterations in neurohumoral mechanisms, orboth, are thought to play a role in causing neurally-
mediated syncope. Because adenosine and its re-
ceptors are involved in some forms of syncope (1–3),
we evaluated the purinergic proﬁle of 4 common
forms of syncope: typical vasovagal syncope (VVS);
situational syncope (which occurs in speciﬁc cir-
cumstances after micturition, defecation, coughing,
swallowing, or gastrointestinal stimulation); carotid
sinus syncope (CSS); and syncope without prodromes
or with very short (2 to 3 s) prodromes and a normal
heart (no prodromes). We compared patients with
neurally-mediated syncope with healthy control
subjects to test the hypothesis that the adenosine
proﬁle differs with the different clinical presentation.
The purinergic proﬁle included an assay of the
baseline adenosine plasma level (APL) and charac-
terization of A2A adenosine receptor (A2A R) expres-
sion and single nucleotide c.1083 C>T polymorphism
(SNP), which is the most common SNP in the A2A
R gene. The method was previously described (1–4).
Clinical and biological characteristics of patients and
control subjects are given in Table 1.
Thus, these ﬁndings demonstrate an association
between adenosine plasmatic levels and unexplained
syncope in patients without prodromes, CSS, and
VVS, who have proﬁles different from normal control
subjects. The clinical manifestation of adenosine de-
pends on its concentration, on adenosine receptor
expression level, and on the presence of receptor
reserve. However, the causal role of this interplay in
the mechanism of syncope is yet to be determined.
Conversely, adenosine is not associated with situa-
tional syncope, which is mainly triggered by well
identiﬁable afferent neural reﬂexes. Patients with
situational syncope showed APL values similar to
those in normal control subjects, although they had
high A2A R expression and a higher rate of the TT
variant. The purinergic proﬁle of situational syncope
patients was never investigated.
Syncope without prodromes and CSS (which is a
similar form of syncope without prodromes or very
short prodromes and an absence of known triggers)
have a similar distinct proﬁle. In these 2 forms, the
role of adenosine may potentially be important in
causing syncope. When APL values are very low,
as in these clinical forms, and are mainly below or
approximately at the KD value for A1A adenosine re-
ceptor (A1 R) of 0.7 mM, even a modest acute increase
in APL may recruit a sufﬁcient number of A1 R, which
is known to be located within the sinus node and in
the atrioventricular node. Their activation causes si-
nus bradycardia and/or atrioventricular block.
For patients with typical VVS, a combination of
neural outﬂow and purinergic activation is likely.
